RT @PokrajacAna: How interesting! Always had a good feeling about #pioglitazone - innocent accused so many times @ABCDiab @organiclemon @Da…
RT @drstak70: #Pioglitazone as a second-line treatment after #metformin might provide a protective effect on #dementia risk among individu…
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
RT @docwas: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a popula…
RT @docwas: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a popula…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
There is something about pioglitazone...beyond the fact that it is not excreted renally and treats fatty liver. Innocent accused. Pleased 2C this study supporting clinical experience @ABCDiab @AbdTahrani @kamleshkhunti @DamianFog @RenalAssoc @Pari_Avari ht
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study https://t.co/isxzzYcz8B
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
Interesting, but likely explained by other factors that differs between patients treated with the various OADs. https://t.co/WSC7S2ZisZ
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. #dementia #pioglitazone https://t.co/rPEjuNXa72
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
RT @kamleshkhunti: Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS…
Pioglitazone associated with lower risk of dementia in people with T2 diabetes https://t.co/UR2JAT4v8v @ABCDiab @redGDPS @Diabetescouk @ADA_DiabetesPro
RT @drstak70: #Pioglitazone as a second-line treatment after #metformin might provide a protective effect on #dementia risk among individu…
#Pioglitazone as a second-line treatment after #metformin might provide a protective effect on #dementia risk among individuals with #Type2Diabetes. https://t.co/ofc197lMgd
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
#Pioglitazone as a second-line treatment after #metformin might provide a protective effect on #dementia risk among individuals with type 2 #diabetes https://t.co/sOJdkMZSoM
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
Perhaps there is something in that insulin resistance theory...! https://t.co/HGfXFzJIVl
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. #dementia #pioglitazone https://t.co/rPEjuNFyIs
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
Otro dato significativo a favor de la Pioglitazona. Un motivo más para seguir individualizando tratamientos. No es la IC el único o principal objetivo, pues no es este el principal riesgo en todos nuestros pacientes. https://t.co/GrESTuVY0J
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
RT @DiabetologiaJnl: Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy:…
How interesting! Always had a good feeling about #pioglitazone - innocent accused so many times @ABCDiab @organiclemon @DamianFog @Roxytonin @Pari_Avari @idasgupta7 https://t.co/hN5VPaHERW
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study. #dementia #pioglitazone https://t.co/rPEjuNXa72